Baxter International ended 2024 on a positive note, overcoming challenges posed by Hurricane Helene and delivering better-than-expected Q4 results. The success of the Novum IQ infusion pump ...

So I'll say, we're very happy with the launch of Novum IQ and where we are. The teams are doing a great job driving this new platform. If you recall, Baxter placed a pretty big bet to internally ...

Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking ...

Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceeding the company’s previously issued guidance 1 Fourth ...

New products like the Novum IQ infusion pump platform should help sales expand. On the bottom line in 2025, Baxter aims to generate $2.45 to $2.55 of adjusted EPS, which is slightly above our ...

Successful launch of Novum IQ infusion pump and 50% growth in infusion business. Positive 2025 guidance with expected sales growth of 5-6%. Baxter International demonstrated solid performance in ...